712 related articles for article (PubMed ID: 10173136)
1. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
3. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
4. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
Liu SZ; Romeis JC
Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
[TBL] [Abstract][Full Text] [Related]
6. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
7. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
Yang BM; Bae EY; Kim J
Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
[TBL] [Abstract][Full Text] [Related]
9. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
10. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
11. A review of new drugs and indications in 2002: financial speculation or better patent care?
Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical industry.
Lewis L
State Health Care Am; 1994; ():23-7. PubMed ID: 10133845
[TBL] [Abstract][Full Text] [Related]
13. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
14. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
15. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
16. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
17. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
18. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
19. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
Grund J; Husbyn H
Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
[TBL] [Abstract][Full Text] [Related]
20. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
